Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female, between 18 and 50 years old, extremes included, having received at least 3 doses of IPV in the past (more than 12 months before the start of the study);~2. In good physical and mental health as determined on the basis of medical history, laboratory screening tests and general physical and psychological examination;~3. Female subjects of childbearing potential must agree to the use of an effective method of birth control throughout the study and up to 3 months after vaccine administration;~4. Willing to adhere to the prohibitions and restrictions specified in this protocol;~5. Willing to adhere to the restrictions of containment for duration as specified in the protocol;~6. Informed Consent Form (ICF) signed voluntarily by the subject before any study-related procedure is performed, indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study.~   Furthermore, willing to adhere to following restrictions as long as shedding will be observed at the end of the containment period:~7. No intention to travel to the Netherlands and to polio endemic countries (updated list will be made available at the start of the study);~8. No professional handling of food, catering or food production activities;~9. Not having household or professional contact with known immunosuppressed people or people without full polio vaccination (i.e. complete primary infant immunization series), e.g. babysitting;~10. No neonatal nursing activities or other professional contact with children under 6 months old;~Exclusion Criteria:~1. A condition that, in the opinion of the Investigator, could compromise the well being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements;~2. Ever having received any OPV in the past;~3. Having Crohn's disease or ulcerative colitis or having had major surgery of the gastrointestinal tract involving significant loss or resection of the bowel;~4. A known allergy, hypersensitivity, or intolerance to the study vaccine, or to any of its components or to any antibiotics;~5. Any confirmed or suspected immunosuppressive or immunodeficiency condition (including human immunodeficiency virus \[HIV\] infection, hepatitis B and C infections or negative for total serum IgA);~6. Chronic administration (i.e., longer than 14 days) of immunosuppressant drugs or other immune-modifying drugs within 6 months prior to the administration of study vaccine or planned use during the study. For instance, for corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day (inhaled and topical steroids are allowed whereas intra-articular and epidural injection/administration of steroids are not allowed);~7. Presence of contraindications to administration of the study vaccine on Day 0: acute severe febrile illness deemed by the Investigator to be a contraindication for vaccination or persistent diarrhea or vomiting;~8. Indications of drug abuse or excessive use of alcohol at Day 0;~9. Being pregnant or breastfeeding. Women of childbearing potential will undergo a pregnancy test at Screening (serum) and at Day 0 (urine). Subjects with a positive pregnancy test will be excluded;~10. Participation in another clinical study within 28 days prior to entry in this study or receipt of any investigational product (drug or vaccine) other than the study vaccine within 28 days prior to the administration of study vaccine, or planned use during the study period;~11. Administration of any vaccine other than the study vaccine within 28 days prior to the administration of study vaccine and during the entire study period;~12. Administration of polio vaccine within 12 months before the start of the study;~13. Having had a transfusion of any blood product or application of immunoglobulins within the 4 weeks prior to the administration of study vaccine or during the study;~14. Subject is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, or is a family member of an employee or the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Novel OPV2 Candidate 1 (Type: EXPERIMENTAL): Participants received one vaccination with novel OPV2 candidate 1 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units \[CCID50\]).
- Novel OPV2 Candidate 2 (Type: EXPERIMENTAL): Participants received one vaccination with novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete